Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

Mirati Therapeutics, Inc. won accelerated approval from the US Food and Drug Administration for its KRAS G12C inhibitor Krazati (adagrasib) for second-line or later treatment of patients with non-small cell lung cancer (NSCLC) who have a KRAS G12C mutation, reaching the market about 18 months after Amgen, Inc.’s Lumakras (sotorasib) in the same indication. It remains to be seen whether Krazati’s labeling gives the drug a competitive advantage, but its list price is above current Lumakras pricing.

San Diego-based Mirati priced its first commercial product at $19,750 for a one-month supply, or $237,000 per year before rebates and other discounts, coming in slightly higher than the current Lumakras price tag of $18,990 per month; the Amgen drug launched at a monthly list price of $17,900 upon FDA approval in May 2021